Absolutely astounding & mind blowing even if 1/3 true, but imagine-- 3 winning platforms in one company.
by ogewen •
It's been a while since I posted. CTIX could be comparable to AAPL in it's infancy, but only time will tell. Their immediate pipeline is remarkable to say the least. Most fledgling biopharma companies have only one drug in its pipeline. CTIX has 3 and all of them are in disparate areas of treatment. Prurisol is the sleeper, but in of itself could be seen as a blockbuster. Psoriasis is a global affliction . The worldwide prevalence of psoriasis is around 2%, (That's 70 to 140 million people) but studies in developed countries have reported higher prevalence rates of on average about 4.6%. Ten percent go on to develop arthritis. Psoriasis is a noncommunicable disease that manifests as a chronic inflammatory skin disease. Being an autoimmune disease it has been linked to other conditions such as ulcerative colitis and many more. It's uniqueness in treating this affliction is that it portends to not only treat symptomatically, but it's application is curative and treated systemically. Studies in Europe which are further along than US show remarkable results. I traveled there recently and heard "off the record" that it is the real deal. We'll see. That alone could give CTIX a $75-100 pps in the immediate future. Now if you throw in B and K into the mix which is getting all the attention and rightfully so since they both are life saving drugs the pps could easily be in the $300-500 range near term. Over the past 20 years of my medical practice treating ocular diseases I have seen antibiotic after antibiotic fail to continue to cure various diseases. Why? Because the offending organisms have become drug resistant. Conjunctivitis (pink eye) is the most contagious disease known to man. Although they mostly are self limiting in most countries even without drug therapy they can be and are diseases that cause permanent blindness in third world countries. This occurs predominantly as a result of secondary infections. The drug resistance of the latest drugs, i.e. Vigamox, Besivance, Zymar creates problems for the practitioner. Often times my own patients will not complete the course of treatment I prescribed because the offending eye feels better and looks better after a few days of usage. Therein lies the problem. The so called "bug" will not be truly destroyed and then mutates into a different microbe. This occurs now with other infectious diseases systemically and topically. I often will refrain from over prescribing to prevent this epidemic problem of drug resistant bacteria. This, however, forces me to have the patient return more frequently to observe the eye to avoid potentially more serious consequences. Multiply this by the millions of time in this country alone and the cost to consumers/insurances are mind boggling. Moreover, when patients are contagious and not working, possibly for 7-10 days, the economic cost to the patient and employer are staggering. Brilacidn, in just this usage alone, could eliminate the need for patient compliance due to their single dosage and defensin-mimetic properties. Just for this one application of Brilacidn the value to Pharma would be in the Billions of dollars in the US. If you extrapolate that to other diseases and world wide usage the profitability of Brilacidn and CTIX boggles the imagination. The mutation of bacteria is advancing exponentially and as a doctor treating eye diseases is beyond alarming. B is a defensin-mimetic that is not susceptible to traditional drug resistance. With B alone CTIX could be in the above pps category. K would explode the pps to even greater heights. I won't bore all the knowledgeable investors on this MB with the salient facts regarding K. I've gone on too long as it is and I apologize for the lack of brevity. I thought it was time for all of us to take a step back and realize how powerful the CTIX arsenal is at this early point of time. Once again please accept my apology for this long quasi- dissertation. I welcome intelligent discussion whether they be pro or con. As you probably surmise I am long and have been since CTIX has been in the $1 pps. GTLA. All the best. Ogewen
